Quantitative Ultrasound of Os Calcis in Postmenopausal Women with Spine and Hip Fractures

2000 ◽  
Vol 3 (3) ◽  
pp. 233-239 ◽  
Author(s):  
Peyman Hadji ◽  
Olaf Hars ◽  
K. Görke ◽  
Günther Emons ◽  
Klaus D. Schulz
Keyword(s):  
Postmenopausal Women ◽  
Hip Fractures ◽  
Quantitative Ultrasound ◽  
Os Calcis

The Clinical Use of Denosumab for the Management of Low Bone Mineral Density in Postmenopausal Women

2012 ◽  
Vol 25 (3) ◽  
pp. 310-318 ◽  
Author(s):  
Kira B. Harris ◽  
Kimberly L. Nealy ◽  
Delilah J. Jackson ◽  
Phillip L. Thornton
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Nuclear Factor Κb ◽  
Bisphosphonate Therapy ◽  
Mineral Density ◽  
Osteoporosis Therapy ◽  
Cost Of Health Care ◽  
Therapy Studies

Osteoporosis is a leading cause of debility and declining quality of life in postmenopausal women worldwide. Treatment of osteoporosis has been ubiquitous throughout the developed world since the mid-1990s, most notably with the introduction of bisphosphonates in 1995. Nonetheless, the incidence of hip fractures increased by 25% between 1990 and 2000, despite advances in osteoporosis therapy. Studies indicate that bone density increases over the first 3 years of bisphosphonate therapy and then plateaus or perhaps even declines, placing these patients at greater risk of fracture. Since hip fractures are associated with increased morbidity, mortality, and increased cost of health care, improvements in treating osteoporosis are critical. Denosumab is a novel monoclonal antibody targeted against the receptor activator of nuclear factor-κB ligand (RANKL) that inhibits osteoclast activity. Initial data suggest that denosumab increases bone mineral density for greater than 3 years. Of greater importance, denosumab has been shown to decrease vertebral fractures by 68%, nonvertebral fractures by 19%, and hip fractures by 42% for at least 36 months. Data also indicate that the safety profile of denosumab is equivalent to other drugs used in osteoporosis management, but potential risks of immunosuppression and cancer have been hypothesized.

Circulating serum level of retinoic acid and hip fractures among postmenopausal women

2018 ◽  
Vol 67 (2) ◽  
pp. 336-341 ◽  
Author(s):  
Xiao-Bin Li ◽  
Tao Liu ◽  
Lei Fan ◽  
Qiang Gao ◽  
Qiang Peng ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Serum Level ◽  
Postmenopausal Women ◽  
Hip Fractures

scholarly journals Soda consumption and the risk of hip fractures in postmenopausal women (1027.6)

2014 ◽  
Vol 28 (S1) ◽  
Author(s):  
Teresa Fung ◽  
Meredith Arasaratnam ◽  
Francine Grodstein ◽  
Jeffrey Katz ◽  
Bernard Rosner ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Hip Fractures ◽  
Soda Consumption

scholarly journals Panoramic radiographs and quantitative ultrasound of the radius and phalanx III to assess bone mineral status in postmenopausal women

2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Katarzyna Grocholewicz ◽  
Joanna Janiszewska-Olszowska ◽  
Magda Aniko-Włodarczyk ◽  
Olga Preuss ◽  
Grzegorz Trybek ◽  
...  
Keyword(s):  
Postmenopausal Women ◽  
Bone Mineral ◽  
Quantitative Ultrasound ◽  
Panoramic Radiographs ◽  
Mineral Status ◽  
Bone Mineral Status

Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom

2011 ◽  
Vol 14 (1) ◽  
pp. 99-107 ◽  
Author(s):  
Lia Gutiérrez ◽  
Neil Roskell ◽  
Jordi Castellsague ◽  
Stephen Beard ◽  
Catherine Rycroft ◽  
...  
Keyword(s):  
United Kingdom ◽  
Incremental Cost ◽  
Postmenopausal Women ◽  
Hip Fractures ◽  
The United Kingdom ◽  
Clinical Burden
Sign in / Sign up

Export Citation Format

Share Document